Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)

NCT00965458 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00965458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00965458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2011
Completion date
April 30, 2014
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

new-onset type 1 diabetes mellitus